Citadel Advisors
DMAC icon

Citadel Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Citadel Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.6K Sell
11,900
-15,800
-57% -$125K ﹤0.01% 12169
2025
Q4 		$220K Buy
+27,700
New +$207K ﹤0.01% 10828
2025
Q2 		– Sell
-800
Closed -$3.03K – 13045
2025
Q1 		$3.03K Sell
800
-8,100
-91% -$46.3K ﹤0.01% 13990
2024
Q4 		$48.3K Buy
8,900
+700
+9% +$3.3K ﹤0.01% 12432
2024
Q3 		$34.4K Buy
8,200
+6,900
+531% +$25.5K ﹤0.01% 12309
2024
Q2 		$3.83K Sell
1,300
-4,600
-78% -$12.6K ﹤0.01% 13544
2024
Q1 		$16.3K Buy
5,900
+4,100
+228% +$11.9K ﹤0.01% 13144
2023
Q4 		$5.11K Buy
1,800
+1,700
+1,700% +$4.21K ﹤0.01% 13455
2023
Q3 		$258 Sell
100
-6,900
-99% -$22.2K ﹤0.01% 14107
2023
Q2 		$30.2K Buy
7,000
+5,900
+536% +$14.3K ﹤0.01% 12346
2023
Q1 		$1.68K Sell
1,100
-500
-31% -$793 ﹤0.01% 14256
2022
Q4 		$2.53K Buy
+1,600
New +$2.15K ﹤0.01% 14322
2021
Q4 		– Sell
-25,400
Closed -$102K – 13953
2021
Q3 		$102K Buy
25,400
+12,400
+95% +$47.5K ﹤0.01% 12838
2021
Q2 		$58K Buy
+13,000
New +$107K ﹤0.01% 13270

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's DMAC Position: Q1 2026 in Review

Citadel Advisors increased its DiaMedica Therapeutics (DMAC) stake by 32% in Q1 2026, buying an estimated $277K and bringing the position to 145,724 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #7686.

Citadel Advisors first reported a position in DMAC in Q1 2021 and has held it in 20 quarters since. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Citadel Advisors held 145,724 shares of DiaMedica Therapeutics worth $987K as of Q1 2026.
  • Citadel Advisors bought 34,987 DiaMedica Therapeutics shares in Q1 2026, an estimated $277K.
  • DiaMedica Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7686 holding.
  • Citadel Advisors first reported a position in DiaMedica Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.